Highest-materiality recent filing
iMDx reports Q1 net loss $4.3M; signs first GALACTIC trial site, advances FDA submission
Q1 revenue ~$32K, gross profit $15K; net loss $4.3M ($0.12/share); non-GAAP net loss $9.6M ($0.28/share).
iMDx signs specimen collection agreement with Quest for GraftAssureCore test
Entered Specimen Collection Agreement with Quest Diagnostics for services supporting GraftAssureCoreTM test.
iMDx submits GraftAssureDx to FDA; Q4 revenue $1.1M, net loss $23.0M
Submitted GraftAssureDx kidney transplant test to FDA on March 25; expects 150-day review and authorization this year.
IMDX raises $26M in registered direct offering; funds heart transplant rejection test development
Gross proceeds ~$26M from 4,525,976 shares/pre-funded warrants at $5.75/unit; net proceeds ~$24.5M.
IMDX Q2 rev $518K, net loss $9.7M; FDA on track for GraftAssureDx submission by year-end
Revenue $518K vs $104K YoY; gross margin 67.6%, up from 62% in Q1.
Oncocyte renames to Insight Molecular Diagnostics (iMDx), ticker changes to IMDX on June 18
Company changed name from Oncocyte Corp to Insight Molecular Diagnostics Inc. effective June 13, 2025.
Oncocyte Q1 revenue $2.14M, gross margin 62%; transplant trial gets IRB approval
Q1 2025 pharma services revenue $2.14M with 62% gross margin, up from 40% in Q4 2024.
Oncocyte Q4 revenue $1.5M, GAAP loss $33.5M; transplant test on track for 2026 FDA authorization
Q4 2024 pharma-services revenue $1.5M; full-year $1.9M; gross margin 40%.
Oncocyte raises $29.1M equity; Bio-Rad invests; funds transplant assay to FDA clearance
Gross proceeds of $29.1M from registered direct ($7.4M) and PIPE ($21.7M) offerings at $2.05/share.
Oncocyte reports Q3 loss of $13.5M; GraftAssure signed 2% US, 9% German transplant volumes
Q3 revenue $115K from pharma services; loss from operations $13.5M ($0.98/sh); non-GAAP loss $5.6M.
Oncocyte raises $10.2M in private placement, adds two major transplant centers as customers
Private placement of 3.46M shares at $2.948/share raises ~$10.2M gross; includes participation from strategic partner Bio-Rad.
Oncocyte reports Q2 revenue $104K, loss $0.36/sh; launches GraftAssure at two centers
Revenue of $104K from pharma services; operating expenses $4.7M; loss from ops $4.5M ($0.36/sh).
Oncocyte appoints Andrea James as CFO, effective June 17, 2024
Andrea James appointed CFO; previously Chief Communications Officer at Axon Enterprise (AXON) and IR roles at Tesla.
Oncocyte Q1 revenue down 41% to $176K; operating loss $9.3M; Bio-Rad partnership
Net revenue $176K, down 41% YoY; operating loss $9.3M (incl. $3.3M contingent consideration loss) vs income $5.9M in Q1 2023.
Oncocyte raises $15.8M in private placement; FY2023 revenue $1.5M, ops loss $25.1M
Private placement of 5.1M shares + pre-funded warrants for 342k shares at $2.92/share; gross proceeds ~$15.8M.
Oncocyte partners with Bio-Rad for global transplant assay; Bio-Rad makes equity investment
10-year collaboration to develop/commercialize GraftAssure RUO and VitaGraft IVD assays on Bio-Rad's ddPCR platform.
On March 4, 2025, the Company promoted James Liu to Vice President Accounting, Controller, Treasurer and Principal Accounting Officer, effective March 10, 2025.
On June 17, 2024, the Board of Directors (the “Board”) of Oncocyte Corporation (the “Company”) appointed Andrea James to serve as the Company’s Chief Financial Officer, effective June 17, 2024.
Max materiality 0.85 · Median 0.57 · Most common event other_material